Bioidentical Hormone Replacement Therapy (BHRT)

What Is Bioidentical Hormone Replacement Therapy (BHRT)?

Bioidentical hormone replacement therapy (BHRT) uses hormones that are structurally identical to those the human body produces — most commonly estradiol, progesterone, and testosterone, and in some protocols DHEA. “Bioidentical” refers to molecular structure, not to whether a product is compounded or commercially manufactured. Many FDA-approved products (for example, transdermal estradiol, oral or vaginal micronized progesterone, and standard testosterone preparations) are themselves bioidentical. The goal of BHRT is to restore hormone levels that have declined with age, surgical menopause, or an underlying endocrine condition, and to relieve the symptoms that accompany that decline.

At ENNU Life in Louisville, BHRT is approached as individualized, lab-guided medicine: dosing is based on measured blood levels, documented symptoms, and a patient’s full clinical picture — not on a fixed protocol.

Hormones, Mechanism, and How Levels Are Measured

Sex hormones act on receptors throughout the body — in the brain, bone, muscle, skin, cardiovascular system, and reproductive organs. As production falls, the downstream effects appear as the familiar symptoms of menopause, perimenopause, and age-related hypogonadism.

• Estradiol (E2) — the primary active estrogen, central to vasomotor symptoms (hot flashes, night sweats), vaginal and urinary tissue health, mood, sleep, and bone density.
• Progesterone — balances estrogen’s effect on the uterine lining; in women with an intact uterus, a progestogen is required alongside estrogen to protect against endometrial overgrowth.
• Testosterone — relevant in both men and women for libido, energy, mood, lean muscle, and overall vitality.

Levels are typically assessed with a blood panel that may include estradiol, progesterone, total and free testosterone, sex hormone–binding globulin (SHBG), FSH, and LH, often alongside thyroid markers and a metabolic panel. Reference ranges are highly assay-dependent and vary by sex, age, menstrual-cycle phase, and whether a person is pre- or postmenopausal, so results must be interpreted by a clinician against the specific laboratory’s reference intervals rather than a single universal number. Saliva testing is sometimes marketed for BHRT but is not considered a reliable basis for dosing in mainstream clinical practice.

Symptoms and Who Should Consider Evaluation

BHRT evaluation is appropriate for adults experiencing symptoms consistent with declining hormone levels. Common reasons to test include:

• Hot flashes, night sweats, and disrupted sleep
• Vaginal dryness, discomfort, or recurrent urinary symptoms (genitourinary syndrome of menopause)
• Mood changes, irritability, anxiety, or “brain fog”
• Low libido and changes in sexual function
• Fatigue, reduced stamina, or loss of muscle and strength
• Irregular cycles in perimenopause
• In men, symptoms of low testosterone such as low energy, low mood, reduced libido, and loss of lean mass

Decisions about therapy weigh symptom severity, timing relative to menopause, and personal risk factors. Hormone therapy is generally most favorable when started in women under 60 or within roughly ten years of menopause onset. It is not appropriate for everyone — a personal history of estrogen-sensitive breast cancer, unexplained vaginal bleeding, active liver disease, or a history of certain blood clots or cardiovascular events typically makes systemic hormone therapy inadvisable. These contraindications are why evaluation by a licensed clinician is essential before starting.

What Optimization Looks Like

Well-managed BHRT is not about pushing levels as high as possible; it is about restoring balance to relieve symptoms at the lowest effective dose. A typical optimization path includes:

• Baseline assessment — symptom history, medical and family history, and appropriate baseline labs.
• Individualized dosing — selecting the hormone, delivery route (transdermal, oral, injectable, or pellet), and dose suited to the patient. Transdermal estrogen, for example, is often preferred over oral when clotting risk is a consideration.
• Endometrial protection — a progestogen for any woman with a uterus receiving systemic estrogen.
• Follow-up and monitoring — rechecking symptoms and labs after initiation, then periodically, and continuing age-appropriate screening such as mammograms and, in men on testosterone, hematocrit and PSA monitoring.
• Ongoing reassessment — adjusting or tapering therapy over time as needs and risk profile change.

The result patients most often report is relief of disruptive symptoms — better sleep, steadier mood, restored libido, and improved energy — within a framework that is monitored and adjusted over time.

Start With an Evaluation

Because hormone needs, risks, and assay reference ranges differ for every individual, the right starting point is a thorough, lab-guided assessment.

Take the ENNU Life Health Assessment to begin your personalized hormone evaluation.

Educational only, not medical advice. This page does not establish a provider–patient relationship. Hormone reference ranges are assay-dependent, and BHRT carries risks and contraindications. Consult a licensed clinician before starting, changing, or stopping any therapy.